Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: FDA OHIP director

This article was originally published in The Gray Sheet

Executive Summary

FDA OHIP director: Lireka Joseph begins serving Aug. 11 as director of the Center for Devices and Radiological Health's Office of Health and Industry Programs. Joseph started her FDA career in 1979 as a medical radiation specialist in the agency's Bureau of Radiological Health and has held various posts in the center's Office of Training and Assistance (OHIP's predecessor), including assistant to the director and acting deputy director. For the past two years, Joseph has served in FDA's Office of the Commissioner as special assistant to the deputy commissioner for operations. She replaces CDRH Deputy Director for Regulations and Policy Joseph Levitt, who has been interim OHIP director since the retirement of former OHIP Director Jim Morrison. In addition, OHIP Division of Device User Programs and Systems Analysis Director Carol Vetter is slated to retire Sept. 31. Vetter's position has been filled for several months on a rotating detail basis by various CDRH staffers, which will continue until a permanent division director is named...

You may also be interested in...

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts